SLAI ON THE STATE OF THE STATE

Contra Costa County

To: Board of Supervisors

From: William Walker, M.D., Health Services Director

Date: July 12, 2016

Subject: Approve Purchase Order with Polymedco Cancer Diagnostics Products, LLC

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent, on behalf of the Health Services Department, to execute a Purchase Order with Polymedco Cancer Diagnostic Products, LLC. to add \$360,000 for a new total of \$480,000, for reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at the Contra Costa Regional Medical Center, with no change in the term from October 1, 2015 through September 30, 2019.

FISCAL IMPACT:

100% Funding is included in the Hospital Enterprise Fund I Budget.

BACKGROUND:

Polymedco's OC-Auto Micro 80 Analyzer with FOBT-CHECKoc reagents is an automated immunochemical fecal occult blood testing system that detects human red cells only, with no interference from red meat, turnips, melons, aspirin, anti-inflammatory drugs and vitamin C. This improvement directs many more of the "right" patients to colonoscopy, leading to the earlier detection of polyps and colorectal cancer.

✓ APP	PROVE	OTHER
▼ RECOMMENDATION OF CNTY ADMINISTRATOR		
Action of Board On: 07/12/2016 APPROVED AS RECOMMENDED OTHER		
Clerks Notes:		
VOTE OF SUPERVISORS		
AYE:	Candace Andersen, District II Supervisor	
	Mary N. Piepho, District III Supervisor	I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
	Karen Mitchoff, District IV	off, District IV ATTESTED: July 12, 2016 Devid Two County Administrator and Clark of the Board of Supervisors
	Supervisor Federal D. Glover, District V Supervisor	
ABSENT:	John Gioia, District I Supervisor	By: Chris Heck, Deputy
Contact:	Anna Roth 370-5101	

Contact: Anna Roth, 3/0-5101

CONSEQUENCE OF NEGATIVE ACTION:

If this Purchase Order is not approved, the CCRMC Clinical Laboratory will not be able to perform patient testing for colorectal cancer.

CHILDREN'S IMPACT STATEMENT:

Not applicable.